Response to teclistamab in patients with R/RMM who had prior BCMA-targeted therapy (ADC or CAR-T therapy). Rates of sCR, CR, VGPR, and PR in 40 patients who were treated with teclistamab are shown. Differences in percentage totals are due to rounding. Responses were assessed by an independent review committee with a cutoff date of 22 August 2023. PR, partial response; sCR, stringent CR.